Analyst Price Target is $12.00
▲ +101.01% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Skye Bioscience in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 101.01% upside from the last price of $5.97.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in Skye Bioscience. This Buy consensus rating has held steady for over two years.
Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.